Influence of lipid lowering therapy on resource utilization in health care - Relevance of the Scandinavian Simvastatin Survival Study (4 S Study) on reducing costs in the Swiss health care setting;EINFLUSS DER MEDIKAMENTOSEN CHOLESTERINSENKUNG AUF DEN RESOURCENVERBRAUCH IM GESUNDHEITSWESEN - BEDEUTUNG DER SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4-S-STUDIE) FUR DIE KOSTENREDUKTION UNTER SCHWEIZER VERHALTNISSEN

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 44, 1997, Pages 1819-1823

  Szucs, T D ^a,d   Luscher T F ^b   Gutzwiller, F ^c  

^a Universitat Mailand   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ANGINA PECTORIS; ARTICLE; HEALTH CARE COST; NONHUMAN; SECONDARY PREVENTION; SWITZERLAND; ADULT; AGED; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; FEMALE; FORECASTING; HEALTH SERVICE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MORTALITY; SCANDINAVIA; STATISTICS; SURVIVAL RATE;

ADULT; AGED; ANGINA PECTORIS; ANTICHOLESTEREMIC AGENTS; COST CONTROL; COST-BENEFIT ANALYSIS; FEMALE; FORECASTING; HEALTH CARE COSTS; HEALTH SERVICES MISUSE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SCANDINAVIA; SIMVASTATIN; SURVIVAL RATE; SWITZERLAND;

EID: 0030814807     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Statistisches Jahrbuch der Schweiz. Zürich: Verlag NZZ, 1997.
2. Sagmeister M, Gessner V, Oggier W, Horisberger B, Gutzwiller F: Die Kosten der koronaren Herzkrankheit in der Schweiz. Eur Heart J 1997 (im Druck).
3. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4 S). Lancet 1994; 344: 1383-1389.
4. Pedersen TJ, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L et al.: Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-1802.
5. VESKA Statistik. Aarau: VESKA, 1995.
6. Arzneimittelkompendium der Schweiz. Basel: Documedis, 1996.
7. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky A et al.: Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960-1968.
8. Drummond MF, McGuire AL, Fletcher AE: Economic evaluation of drug therapy for hypercholesterolemia in the United Kingdom. York: University of York, Centre for Health Economics, 1993.
9. Martens LL, Rutten FFM, Erkelsens DW, Ascoop CAPL: Costeffectiveness of cholesterol lowering therapy in the Netherlands. Am J Med 1987; 4A: 54S-58S.
10. Unger F: European survey on open heart surgery, PTCA and cardiac catheterisation in 1992. Ann Eur Acad Sci Art 1993; 6: 12-66.
11. Röthlisberger C, Meier B, Urban P: Herzeingriffe in der Schweiz 1993. Schweiz Rundsch Med Prax 1995; 84: 402-411.
12. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H: Costeffectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary artery disease. N Engl J Med 1997; 336: 332-336.
13. Hunziker P, Bertel O: Sekundärprophylaxe bei bekannter chronischer koronarer Herzkrankheit. Schweiz Med Wochenschr 1997; 127. 254-260.
14. Olivier M, Poole-Wilson P, Shepherd J, Tikkanen MJ: Lower patients' cholesterol now. Trial evidence shows clear benefits from secondary prevention. Br Med J 1995; 31: 1280-1281.